# Lumen Bioscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lumen-bioscience

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.lumenbioscience.com
- Total disclosed funding: $57M
- Latest round: Series C (Oct 8, 2025)
- Investors on record: 5

## About

Lumen Bioscience, Inc. specializes in the development of biologic drugs utilizing patented technology derived from spirulina, aiming to deliver innovative therapeutic solutions.Founded in 2017, Lumen Bioscience, Inc. is based in Seattle, US. The company focuses on creating next-generation biologic treatments and has successfully completed 4 deals. The latest funding round was a Grant of USD 4.00 mn from the Medical Technology Enterprise Consortium on September 24, 2020, bringing the total amount raised to USD 16.00 mn. The company is co-founded by Brian Finrow and Jim Roberts, with Brian Finrow serving as the CEO.Lumen Bioscience primarily focuses on developing next-generation biologic drugs using its patented technology that leverages the food algae spirulina for delivering therapeutic proteins. Their core product offerings include LMN-801, an oral therapeutic aimed at weight loss that uniquely avoids the muscle-wasting side effects commonly associated with GLP-1 drugs, and LMN-201, an oral capsule designed to treat C. difficile infections. These products aim to provide greater patient convenience and efficacy compared to existing treatments, targeting significant unmet medical needs in various therapeutic areas, including metabolic disease and gastrointestinal infections. These products are positioned for global markets, addressing health challenges prevalent in North America, Europe, and other regions with high incidences of metabolic disorders and gastrointestinal diseases.Lumen Bioscience's revenue model is primarily structured around partnerships and collaborations, focusing on strategic alliances to facilitate the development and distribution of its biologic products. Transactions typically involve agreements with healthcare providers and pharmaceutical companies, allowing for the distribution of their flagship products, LMN-801 and LMN-201, directly to end-users in clinical settings. The company's offerings cater to both B2B and direct-to-consumer markets, enhancing accessibility for patients suffering from conditions such as obesity and C. difficile infections. Given the innovative nature of their oral biologics, Lumen aims to establish pricing plans that reflect the competitive landscape while ensuring affordability and broader access for patients, though specific pricing details are not disclosed.Lumen Bioscience plans to leverage its recent USD 4.00 mn grant funding to advance the development of its product pipeline, including the anticipated launch of LMN-801 and LMN-201 into new markets. The company is targeting expansion into Europe and Asia by 2025, aiming to address the growing demand for effective treatments in these regions. The funding will support research and development efforts, regulatory approvals, and marketing strategies necessary to establish a presence in these new geographic areas.  In October 2025, Lumen Bioscience, Inc. raised USD 30 million in series C funding led by returning investor West River Group, with participation from new investor Gates Family Foundation. Individuals and other unspecified investors also participated in the round. The company will use the funding to advance clinical trials, prepare for product launch, and grow its operations.

## Funding rounds

- Series C, Oct 8, 2025, $30M — Gates Family Foundation, West River Group
- Series B, Sep 1, 2020, $16M — Columbia Pacific Advisors, West River Group, Planetary Technologies, Avista Development
- Series A, Dec 5, 2017, $11M — Planetary Technologies, Avista Development

## Investors

- Planetary Technologies (https://capitalatlas.ai/funds/planetary-technologies) — Series A, Series B
- Avista Development — Series A, Series B
- Columbia Pacific Advisors (https://capitalatlas.ai/funds/columbia-pacific-advisors) — Series B
- West River Group — Series B, Series C
- Gates Family Foundation — Series C